Free Trial

Arcus Biosciences (RCUS) Financials

Arcus Biosciences logo
$8.43 +0.32 (+3.88%)
As of 03:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Annual Income Statements for Arcus Biosciences

Annual Income Statements for Arcus Biosciences

This table shows Arcus Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-18 -53 -50 -85 -123 53 -267 -307 -283
Consolidated Net Income / (Loss)
-18 -53 -50 -85 -123 53 -267 -307 -283
Net Income / (Loss) Continuing Operations
-18 -53 -50 -85 -123 53 -267 -307 -283
Total Pre-Tax Income
-18 -53 -50 -85 -123 55 -266 -301 -282
Total Operating Income
-18 -53 -55 -89 -124 54 -280 -340 -330
Total Gross Profit
0.00 1.41 8.35 15 78 383 112 117 258
Total Revenue
0.00 1.41 8.35 15 78 383 112 117 258
Operating Revenue
0.00 1.41 8.35 15 78 383 112 117 258
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
18 55 63 104 202 329 392 457 588
Selling, General & Admin Expense
3.94 7.64 14 25 43 72 104 117 120
Research & Development Expense
14 47 50 78 159 257 288 340 448
Impairment Charge
- - - - - - - - 20
Total Other Income / (Expense), net
0.21 0.36 5.27 4.00 1.00 1.00 14 39 48
Interest Expense
- - - - 0.00 0.00 2.00 2.00 4.00
Interest & Investment Income
0.21 -0.42 0.34 -1.20 - - - - 52
Income Tax Expense
- - - 0.00 0.00 2.00 1.00 6.00 1.00
Basic Earnings per Share
($20.80) - - - - - ($3.71) ($4.15) ($3.14)
Weighted Average Basic Shares Outstanding
863.98K 1.83M 34.62M 43.83M 54.80M 69.30M 72M 74M 90.10M
Diluted Earnings per Share
($20.80) - - - - - ($3.71) ($4.15) ($3.14)
Weighted Average Diluted Shares Outstanding
863.98K 1.83M 34.62M 43.83M 54.80M 74M 72M 74M 90.10M
Weighted Average Basic & Diluted Shares Outstanding
863.98K 1.83M 34.62M 43.83M 54.79M 71.06M 73.01M 90.86M 105.84M

Quarterly Income Statements for Arcus Biosciences

This table shows Arcus Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-65 -67 -80 -75 -71 -81 -4.00 -93 -92 -94
Consolidated Net Income / (Loss)
-65 -67 -80 -75 -71 -81 -4.00 -93 -92 -94
Net Income / (Loss) Continuing Operations
-65 -67 -80 -75 -71 -81 -4.00 -93 -92 -94
Total Pre-Tax Income
-65 -67 -78 -74 -69 -80 -4.00 -93 -92 -93
Total Operating Income
-70 -74 -86 -83 -80 -91 -16 -106 -105 -103
Total Gross Profit
33 34 25 29 32 31 145 39 48 26
Total Revenue
33 34 25 29 32 31 145 39 48 26
Operating Revenue
33 34 25 29 32 31 145 39 48 26
Total Operating Expenses
103 108 111 112 112 122 161 145 153 129
Selling, General & Admin Expense
26 28 30 28 30 29 32 30 30 28
Research & Development Expense
77 80 81 84 82 93 109 115 123 101
Total Other Income / (Expense), net
5.00 7.00 8.00 9.00 11 11 12 13 13 10
Interest Expense
0.00 1.00 1.00 0.00 1.00 - 1.00 0.00 1.00 2.00
Income Tax Expense
0.00 - 2.00 1.00 2.00 1.00 0.00 0.00 0.00 1.00
Basic Earnings per Share
- - ($1.09) ($1.04) ($0.94) ($1.08) ($0.05) ($1.02) ($1.00) ($1.07)
Weighted Average Basic Shares Outstanding
72.20M 72M 73M 73.20M 74.60M 74M 86.20M 91.10M 91.40M 90.10M
Diluted Earnings per Share
- - ($1.09) ($1.04) ($0.94) ($1.08) ($0.05) ($1.02) ($1.00) ($1.07)
Weighted Average Diluted Shares Outstanding
72.20M 72M 73M 73.20M 74.60M 74M 86.20M 91.10M 91.40M 90.10M
Weighted Average Basic & Diluted Shares Outstanding
72.41M 73.01M 73.11M 74.50M 74.86M 90.86M 90.95M 91.43M 91.51M 105.84M

Annual Cash Flow Statements for Arcus Biosciences

This table details how cash moves in and out of Arcus Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
18 33 -27 -13 116 -23 58 -79 23
Net Cash From Operating Activities
-13 -25 -43 -73 111 -256 438 -306 -170
Net Cash From Continuing Operating Activities
-13 -25 -43 -73 111 -256 438 -306 -170
Net Income / (Loss) Continuing Operations
-18 -53 -50 -85 -123 53 -267 -307 -283
Consolidated Net Income / (Loss)
-18 -53 -50 -85 -123 53 -267 -307 -283
Depreciation Expense
1.31 2.61 3.66 3.58 3.00 4.00 6.00 8.00 10
Amortization Expense
0.00 0.00 -1.75 -2.64 0.00 5.00 0.00 -19 -25
Non-Cash Adjustments To Reconcile Net Income
0.09 0.81 5.32 12 22 41 777 96 131
Changes in Operating Assets and Liabilities, net
3.62 25 -0.29 -1.50 209 -359 -78 -84 -3.00
Net Cash From Investing Activities
-39 -49 -113 59 -434 -4.00 -413 194 -84
Net Cash From Continuing Investing Activities
-39 -49 -113 59 -434 -4.00 -413 194 -84
Purchase of Property, Plant & Equipment
-4.10 -5.51 -3.74 -1.93 -3.00 -26 -6.00 -24 -6.00
Purchase of Investments
-34 -97 -262 -248 -740 -719 -1,241 -788 -1,043
Sale and/or Maturity of Investments
0.00 53 152 309 309 741 837 1,006 965
Other Investing Activities, net
-1.00 - - - 0.00 0.00 -3.00 0.00 0.00
Net Cash From Financing Activities
70 107 129 1.12 439 237 33 33 277
Net Cash From Continuing Financing Activities
70 107 129 1.12 439 237 33 33 277
Issuance of Debt
- - - - - - 0.00 0.00 47
Issuance of Common Equity
0.28 0.89 129 1.22 439 232 23 33 237
Other Financing Activities, net
0.00 -0.37 - - 0.00 5.00 10 0.00 -7.00
Cash Interest Paid
- - - - - - 0.00 0.00 1.00
Cash Income Taxes Paid
- - - - 0.00 0.00 3.00 5.00 0.00

Quarterly Cash Flow Statements for Arcus Biosciences

This table details how cash moves in and out of Arcus Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-55 -12 32 -8.00 -46 -57 58 -29 45 -51
Net Cash From Operating Activities
-81 -70 -98 -57 -63 -88 -2.00 -94 26 -100
Net Cash From Continuing Operating Activities
-81 -70 -98 -57 -63 -88 -2.00 -94 26 -100
Net Income / (Loss) Continuing Operations
-65 -67 -80 -75 -71 -81 -4.00 -93 -92 -94
Consolidated Net Income / (Loss)
-65 -67 -80 -75 -71 -81 -4.00 -93 -92 -94
Depreciation Expense
2.00 1.00 2.00 2.00 1.00 3.00 3.00 2.00 2.00 3.00
Amortization Expense
- -2.00 -4.00 -4.00 1.00 -12 -6.00 -7.00 -6.00 -6.00
Non-Cash Adjustments To Reconcile Net Income
25 7.00 27 18 10 41 55 29 32 15
Changes in Operating Assets and Liabilities, net
-43 -9.00 -43 2.00 -4.00 -39 -50 -25 90 -18
Net Cash From Investing Activities
23 47 129 26 11 28 -169 63 -29 51
Net Cash From Continuing Investing Activities
23 47 129 26 11 28 -169 63 -29 51
Purchase of Property, Plant & Equipment
-2.00 - -3.00 -5.00 -10 -6.00 -4.00 - -1.00 -1.00
Purchase of Investments
-322 -156 -154 -239 -280 -115 -387 -206 -278 -172
Sale and/or Maturity of Investments
344 203 286 270 301 149 222 269 250 224
Net Cash From Financing Activities
3.00 11 1.00 23 6.00 3.00 229 2.00 48 -2.00
Net Cash From Continuing Financing Activities
3.00 11 1.00 23 6.00 3.00 229 2.00 48 -2.00
Issuance of Common Equity
3.00 6.00 1.00 23 6.00 3.00 229 3.00 2.00 3.00
Other Financing Activities, net
- 5.00 - - - - - - -1.00 -5.00

Annual Balance Sheets for Arcus Biosciences

This table presents Arcus Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets
190 275 203 772 1,592 1,345 1,095 1,150
Total Current Assets
177 259 193 736 1,262 1,067 831 1,016
Cash & Equivalents
98 71 58 173 148 206 127 150
Short-Term Investments
77 185 130 555 351 803 632 828
Prepaid Expenses
1.14 2.32 4.05 5.47 18 19 34 18
Other Current Assets
- 0.00 0.13 1.05 745 39 38 20
Plant, Property, & Equipment, net
11 11 9.33 11 32 35 51 47
Total Noncurrent Assets
2.39 4.87 1.08 26 298 243 213 87
Long-Term Investments
0.68 4.38 0.00 6.44 182 129 107 14
Other Noncurrent Operating Assets
1.71 0.49 1.08 19 116 114 106 73
Total Liabilities & Shareholders' Equity
190 275 203 772 1,592 1,345 1,095 1,150
Total Liabilities
37 40 39 270 750 688 633 665
Total Current Liabilities
13 17 23 122 166 193 184 226
Accounts Payable
3.82 3.10 4.70 16 10 20 17 18
Current Deferred Revenue
5.00 6.25 7.00 75 102 97 91 85
Other Current Liabilities
0.77 1.56 1.48 3.57 54 76 76 123
Total Noncurrent Liabilities
24 23 17 148 584 495 449 439
Long-Term Debt
- - - - - - 0.00 48
Noncurrent Deferred Revenue
23 21 16 133 462 355 307 234
Other Noncurrent Operating Liabilities
0.57 1.79 0.81 16 122 140 142 157
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-72 235 164 502 842 657 462 485
Total Preferred & Common Equity
-72 235 164 502 842 657 462 485
Total Common Equity
-72 235 164 502 842 657 462 485
Common Stock
0.95 358 369 830 1,118 1,206 1,311 1,617
Retained Earnings
-73 -123 -205 -328 -275 -542 -849 -1,132

Quarterly Balance Sheets for Arcus Biosciences

This table presents Arcus Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
1,394 1,254 1,220 1,191 1,293 1,186 1,252
Total Current Assets
1,101 1,015 986 882 1,064 1,022 1,127
Cash & Equivalents
218 238 230 184 185 156 201
Short-Term Investments
831 716 700 615 810 813 888
Prepaid Expenses
22 28 22 31 34 25 22
Other Current Assets
27 33 34 52 35 28 16
Plant, Property, & Equipment, net
34 37 45 50 51 49 48
Total Noncurrent Assets
259 202 189 259 178 115 77
Long-Term Investments
143 90 80 151 100 40 2.00
Other Noncurrent Operating Assets
116 112 109 108 78 75 75
Total Liabilities & Shareholders' Equity
1,394 1,254 1,220 1,191 1,293 1,186 1,252
Total Liabilities
695 654 654 671 586 551 687
Total Current Liabilities
177 179 180 200 204 199 215
Accounts Payable
11 28 12 17 16 15 13
Current Deferred Revenue
103 97 103 103 124 113 105
Other Current Liabilities
2.98 54 65 80 64 71 97
Total Noncurrent Liabilities
518 475 474 471 382 352 472
Long-Term Debt
- - - - - - 47
Noncurrent Deferred Revenue
383 330 330 326 242 214 289
Other Noncurrent Operating Liabilities
135 145 144 145 140 138 136
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
699 600 566 520 707 635 565
Total Preferred & Common Equity
699 600 566 520 707 635 565
Total Common Equity
699 600 566 520 707 635 565
Common Stock
1,183 1,226 1,267 1,291 1,561 1,582 1,602
Retained Earnings
-475 -622 -697 -768 -853 -946 -1,038
Accumulated Other Comprehensive Income / (Loss)
-9.80 -4.00 -4.00 -3.00 -1.00 -1.00 1.00

Annual Metrics and Ratios for Arcus Biosciences

This table displays calculated financial ratios and metrics derived from Arcus Biosciences' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - - - - -
Revenue Growth
0.00% 0.00% 491.15% 79.58% 420.00% 391.03% -70.76% 4.46% 120.51%
EBITDA Growth
0.00% -196.74% 4.05% -71.93% -45.33% 153.33% -503.13% -20.16% -11.29%
EBIT Growth
0.00% -189.66% 5.18% -67.23% -47.29% 144.72% -580.00% -13.26% -10.37%
NOPAT Growth
0.00% -193.92% -2.65% -61.70% -39.78% 159.95% -476.66% -21.43% 2.94%
Net Income Growth
0.00% -195.39% 6.57% -70.81% -45.20% 143.09% -603.77% -14.98% 7.82%
EPS Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11.86% 24.34%
Operating Cash Flow Growth
0.00% -93.60% -71.58% -70.86% 251.10% -330.63% 271.09% -169.86% 44.44%
Free Cash Flow Firm Growth
0.00% 0.00% -134.58% -82.21% 290.96% -381.15% 230.51% -170.63% 44.13%
Invested Capital Growth
0.00% 0.00% -15.40% 5.99% -852.93% 169.16% -398.76% 16.01% -13.61%
Revenue Q/Q Growth
0.00% 0.00% 3.88% 120.20% 0.28% 898.62% -74.11% -2.50% -1.90%
EBITDA Q/Q Growth
0.00% 0.00% 8.23% -5.64% -40.96% 123.51% -374.03% -7.64% -19.79%
EBIT Q/Q Growth
0.00% 0.00% 8.74% -5.86% -40.41% 119.75% -416.02% -4.91% -23.60%
NOPAT Q/Q Growth
0.00% 0.00% -0.26% -4.78% -38.16% 126.66% -371.12% -5.26% -3.77%
Net Income Q/Q Growth
0.00% 0.00% 1.81% -5.35% -40.41% 119.03% -435.69% -4.78% -4.81%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -111.78% -3.33% -26.77% -4.87% -1.81% -6.25% -7.59%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% -3.50% -23.13% -45.36% 22.28% -8.88% -1.38%
Invested Capital Q/Q Growth
0.00% 0.00% -18.18% -23.66% 3.30% 180.19% 2.48% 6.05% 4.18%
Profitability Metrics
- - - - - - - - -
Gross Margin
0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
0.00% -3,542.39% -574.94% -550.45% -153.85% 16.71% -230.36% -264.96% -133.72%
Operating Margin
0.00% -3,782.09% -656.76% -591.39% -158.97% 14.10% -250.00% -290.60% -127.91%
EBIT Margin
0.00% -3,727.25% -597.83% -556.72% -157.69% 14.36% -235.71% -255.56% -127.91%
Profit (Net Income) Margin
0.00% -3,756.69% -593.73% -564.73% -157.69% 13.84% -238.39% -262.39% -109.69%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 96.36% 100.38% 101.99% 100.35%
Interest Burden Percent
98.83% 100.79% 99.31% 101.44% 100.00% 100.00% 100.76% 100.67% 85.45%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 3.64% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% -34.50% -25.51% -42.48% -36.93% 7.89% -35.62% -54.87% -59.77%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% -212.26% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% -27.65% -21.46% -34.94% -25.22% 4.65% -17.98% -24.51% -29.40%
Return on Assets (ROA)
0.00% -27.87% -21.31% -35.44% -25.22% 4.48% -18.18% -25.16% -25.21%
Return on Common Equity (ROCE)
0.00% 16.22% -10.67% -42.48% -36.93% 7.89% -35.62% -54.87% -59.77%
Return on Equity Simple (ROE_SIMPLE)
0.00% 73.39% -21.11% -51.70% -24.49% 6.29% -40.64% -66.45% -58.35%
Net Operating Profit after Tax (NOPAT)
-13 -37 -38 -62 -87 52 -196 -238 -231
NOPAT Margin
0.00% -2,647.47% -459.73% -413.98% -111.28% 13.59% -175.00% -203.42% -89.53%
Net Nonoperating Expense Percent (NNEP)
0.00% -17.77% -5.12% -10.07% -7.84% 0.14% -7.81% -6.89% -5.75%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - -29.83% -51.52% -43.34%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 540.41% 162.41% 168.19% 55.13% 18.80% 92.86% 100.00% 46.51%
R&D to Revenue
0.00% 3,341.68% 594.35% 523.21% 203.85% 67.10% 257.14% 290.60% 173.64%
Operating Expenses to Revenue
0.00% 3,882.09% 756.76% 691.39% 258.97% 85.90% 350.00% 390.60% 227.91%
Earnings before Interest and Taxes (EBIT)
-18 -53 -50 -84 -123 55 -264 -299 -330
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-17 -50 -48 -83 -120 64 -258 -310 -345
Valuation Ratios
- - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 2.04 2.83 3.36 3.38 2.28 3.09 2.81
Price to Tangible Book Value (P/TBV)
0.00 0.00 2.04 2.83 3.36 3.38 2.28 3.09 2.81
Price to Revenue (P/Rev)
0.00 84.93 57.32 30.88 21.61 7.42 13.37 12.22 5.28
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 53.64 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 1.86% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 13.43 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 120.18 26.08 18.33 12.18 5.64 3.21 4.82 1.62
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 33.78 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 39.31 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 41.55 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 8.56 0.00 0.82 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 7.82 0.00 0.81 0.00 0.00
Leverage & Solvency
- - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10
Financial Leverage
0.00 -1.15 -1.12 -1.13 -1.39 -1.05 -1.21 -1.79 -1.91
Leverage Ratio
0.00 1.24 1.20 1.20 1.46 1.76 1.96 2.18 2.37
Compound Leverage Factor
0.00 1.25 1.19 1.22 1.46 1.76 1.97 2.20 2.03
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.01%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.01%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 147.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% -47.01% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 90.99%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.14
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.74
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.14
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.21
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.09
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.21
Altman Z-Score
0.00 1.56 7.05 5.38 3.68 3.21 0.96 0.18 -0.05
Noncontrolling Interest Sharing Ratio
0.00% 147.01% 58.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - -
Current Ratio
0.00 13.90 15.29 8.49 6.05 7.60 5.53 4.52 4.50
Quick Ratio
0.00 13.81 15.15 8.30 5.99 3.01 5.23 4.13 4.33
Cash Flow Metrics
- - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -15 -35 -64 122 -342 446 -315 -176
Operating Cash Flow to CapEx
-315.78% -454.46% -1,148.70% -3,816.21% 3,700.00% -984.62% 7,300.00% -1,275.00% -2,833.33%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 223.00 -157.50 -44.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 219.00 -153.00 -42.50
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 216.00 -165.00 -44.00
Efficiency Ratios
- - - - - - - - -
Asset Turnover
0.00 0.01 0.04 0.06 0.16 0.32 0.08 0.10 0.23
Accounts Receivable Turnover
0.00 56.52 154.69 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.13 0.75 1.47 7.75 17.89 3.34 2.72 5.27
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 6.46 2.36 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 6.46 2.36 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - -
Invested Capital
0.00 -23 -26 -24 -233 161 -481 -404 -459
Invested Capital Turnover
0.00 -0.13 -0.34 -0.60 -0.61 -10.67 -0.70 -0.26 -0.60
Increase / (Decrease) in Invested Capital
0.00 -23 -3.47 1.56 -208 394 -642 77 -55
Enterprise Value (EV)
0.00 170 218 275 950 2,162 359 564 419
Market Capitalization
120 120 479 463 1,685 2,843 1,497 1,430 1,363
Book Value per Share
$0.00 ($39.56) $5.29 $3.57 $7.74 $11.99 $9.07 $6.17 $5.30
Tangible Book Value per Share
$0.00 ($39.56) $5.29 $3.57 $7.74 $11.99 $9.07 $6.17 $5.30
Total Capital
0.00 154 235 164 502 842 657 462 533
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 48
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 48
Net Debt
0.00 -176 -261 -188 -735 -681 -1,138 -866 -944
Capital Expenditures (CapEx)
4.10 5.51 3.74 1.93 3.00 26 6.00 24 6.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -12 -15 -18 -115 597 -135 -112 -188
Debt-free Net Working Capital (DFNWC)
0.00 164 242 170 614 1,096 874 647 790
Net Working Capital (NWC)
0.00 164 242 170 614 1,096 874 647 790
Net Nonoperating Expense (NNE)
5.24 16 11 23 36 -0.96 71 69 52
Net Nonoperating Obligations (NNO)
0.00 -176 -261 -188 -735 -681 -1,138 -866 -944
Total Depreciation and Amortization (D&A)
1.31 2.61 1.91 0.94 3.00 9.00 6.00 -11 -15
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -818.12% -173.96% -121.81% -146.79% 155.87% -120.54% -95.73% -72.87%
Debt-free Net Working Capital to Revenue
0.00% 11,616.63% 2,897.32% 1,133.33% 787.37% 286.16% 780.36% 552.99% 306.20%
Net Working Capital to Revenue
0.00% 11,616.63% 2,897.32% 1,133.33% 787.37% 286.16% 780.36% 552.99% 306.20%
Earnings Adjustments
- - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.14)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 44.53M 45.97M 70.88M 69.35M 72M 74M 90.10M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($3.14)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 44.53M 45.97M 70.88M 73.97M 72M 74M 90.10M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 34.62M 43.83M 54.79M 71.06M 73.01M 90.86M 105.84M
Normalized Net Operating Profit after Tax (NOPAT)
-13 -37 -38 -62 -87 52 -196 -238 -217
Normalized NOPAT Margin
0.00% -2,647.47% -459.73% -413.98% -111.28% 13.59% -175.00% -203.42% -84.11%
Pre Tax Income Margin
0.00% -3,756.69% -593.73% -564.73% -157.69% 14.36% -237.50% -257.27% -109.30%
Debt Service Ratios
- - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -132.00 -149.50 -82.50
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -98.00 -119.00 -57.75
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -135.00 -161.50 -84.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 -101.00 -131.00 -59.25
Payout Ratios
- - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -0.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Arcus Biosciences

This table displays calculated financial ratios and metrics derived from Arcus Biosciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
248.80% -90.41% 38.89% 7.41% -3.03% -8.82% 480.00% 34.48% 50.00% -16.13%
EBITDA Growth
16.69% -123.50% -23.44% -18.75% -4.76% -32.84% 92.41% -28.95% -43.94% -19.10%
EBIT Growth
16.64% -123.44% -14.93% -12.12% -4.62% -21.21% 96.10% -25.68% -33.82% -28.75%
NOPAT Growth
10.41% -118.56% -28.36% -20.29% -14.29% -22.97% 81.40% -27.71% -31.25% -13.19%
Net Income Growth
16.64% -123.97% -17.65% -11.94% -9.23% -20.90% 95.00% -24.00% -29.58% -16.05%
EPS Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 95.41% 1.92% -6.38% 0.93%
Operating Cash Flow Growth
-50.68% -13.03% -114.98% 12.31% 22.22% -25.71% 97.96% -64.91% 141.27% -13.64%
Free Cash Flow Firm Growth
357.23% 614.29% -158.11% -150.14% -148.97% -123.84% 58.52% -4.63% 79.45% 87.85%
Invested Capital Growth
-145.67% -398.76% 18.65% 15.22% 12.82% 16.01% 12.61% 15.77% -11.40% -13.61%
Revenue Q/Q Growth
22.22% 3.03% -26.47% 16.00% 10.34% -3.13% 367.74% -73.10% 23.08% -45.83%
EBITDA Q/Q Growth
1.56% -6.35% -17.91% 3.80% 13.16% -34.85% 92.77% -1,533.33% 3.06% -11.58%
EBIT Q/Q Growth
1.52% -1.54% -16.67% 3.90% 8.11% -17.65% 96.25% -3,000.00% 2.15% -13.19%
NOPAT Q/Q Growth
-1.45% -5.71% -16.22% 3.49% 3.61% -13.75% 82.42% -562.50% 0.94% 1.90%
Net Income Q/Q Growth
2.99% -3.08% -19.40% 6.25% 5.33% -14.08% 95.06% -2,225.00% 1.08% -2.17%
EPS Q/Q Growth
0.00% 0.00% 0.00% 4.59% 9.62% -14.89% 0.00% -1,940.00% 1.96% -7.00%
Operating Cash Flow Q/Q Growth
-24.62% 13.58% -40.00% 41.84% -10.53% -39.68% 97.73% -4,600.00% 127.66% -484.62%
Free Cash Flow Firm Q/Q Growth
-11.43% 142.43% -127.45% 14.92% 13.50% -18.02% 52.24% -114.58% 83.01% 30.20%
Invested Capital Q/Q Growth
5.82% 2.48% 7.69% 0.00% 3.15% 6.05% 3.96% 3.61% -28.07% 4.18%
Profitability Metrics
- - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-190.91% -197.06% -316.00% -262.07% -206.25% -287.10% -4.14% -251.28% -197.92% -407.69%
Operating Margin
-212.12% -217.65% -344.00% -286.21% -250.00% -293.55% -11.03% -271.79% -218.75% -396.15%
EBIT Margin
-196.97% -194.12% -308.00% -255.17% -212.50% -258.06% -2.07% -238.46% -189.58% -396.15%
Profit (Net Income) Margin
-196.97% -197.06% -320.00% -258.62% -221.88% -261.29% -2.76% -238.46% -191.67% -361.54%
Tax Burden Percent
100.00% 100.00% 102.56% 101.35% 102.90% 101.25% 100.00% 100.00% 100.00% 101.08%
Interest Burden Percent
100.00% 101.52% 101.30% 100.00% 101.47% 100.00% 133.33% 100.00% 101.10% 90.29%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
12.82% -35.62% -39.95% -43.70% -48.08% -54.87% -35.35% -41.47% -49.77% -59.77%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-76.32% -14.81% -26.20% -22.90% -19.73% -24.75% -0.39% -48.96% -40.82% -91.05%
Return on Assets (ROA)
-76.32% -15.03% -27.23% -23.21% -20.60% -25.06% -0.51% -48.96% -41.27% -83.10%
Return on Common Equity (ROCE)
12.82% -35.62% -39.95% -43.70% -48.08% -54.87% -35.35% -41.47% -49.77% -59.77%
Return on Equity Simple (ROE_SIMPLE)
11.38% 0.00% -46.50% -50.71% -56.35% 0.00% -32.67% -39.21% -47.79% 0.00%
Net Operating Profit after Tax (NOPAT)
-49 -52 -60 -58 -56 -64 -11 -74 -74 -72
NOPAT Margin
-148.48% -152.35% -240.80% -200.34% -175.00% -205.48% -7.72% -190.26% -153.13% -277.31%
Net Nonoperating Expense Percent (NNEP)
-1.65% -1.67% -1.66% -1.48% -1.40% -1.73% 0.67% -1.86% -1.86% -2.42%
Return On Investment Capital (ROIC_SIMPLE)
- -7.88% - - - -13.79% - - - -13.53%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
78.79% 82.35% 120.00% 96.55% 93.75% 93.55% 22.07% 76.92% 62.50% 107.69%
R&D to Revenue
233.33% 235.29% 324.00% 289.66% 256.25% 300.00% 75.17% 294.87% 256.25% 388.46%
Operating Expenses to Revenue
312.12% 317.65% 444.00% 386.21% 350.00% 393.55% 111.03% 371.79% 318.75% 496.15%
Earnings before Interest and Taxes (EBIT)
-65 -66 -77 -74 -68 -80 -3.00 -93 -91 -103
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-63 -67 -79 -76 -66 -89 -6.00 -98 -95 -106
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.70 2.28 2.22 2.62 2.57 3.09 2.00 2.18 2.47 2.81
Price to Tangible Book Value (P/TBV)
2.70 2.28 2.22 2.62 2.57 3.09 2.00 2.18 2.47 2.81
Price to Revenue (P/Rev)
4.36 13.37 11.19 12.27 11.14 12.22 5.96 5.61 5.32 5.28
Price to Earnings (P/E)
23.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
4.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
1.61 3.21 2.42 3.92 3.23 4.82 1.34 1.52 1.35 1.62
Enterprise Value to EBITDA (EV/EBITDA)
7.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
8.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
9.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
1.56 0.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
1.91 0.81 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.10
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.10
Financial Leverage
-1.56 -1.21 -1.71 -1.74 -1.76 -1.79 -1.64 -1.68 -1.84 -1.91
Leverage Ratio
1.80 1.96 2.00 2.05 2.12 2.18 1.95 2.00 2.25 2.37
Compound Leverage Factor
1.80 1.99 2.03 2.05 2.15 2.18 2.60 2.00 2.28 2.14
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.68% 9.01%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.68% 9.01%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 92.32% 90.99%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.16 -0.14
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.63 2.74
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.16 -0.14
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.21 -0.21
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.69 4.09
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.21 -0.21
Altman Z-Score
2.10 1.44 1.22 1.25 0.89 0.84 1.50 1.17 0.90 0.60
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
6.21 5.53 5.67 5.48 4.41 4.52 5.22 5.14 5.24 4.50
Quick Ratio
5.94 5.23 5.33 5.17 4.00 4.13 4.88 4.87 5.07 4.33
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
243 590 -162 -138 -119 -141 -67 -144 -25 -17
Operating Cash Flow to CapEx
-4,050.00% 0.00% -3,266.67% -1,140.00% -630.00% -1,466.67% -50.00% 0.00% 2,600.00% -10,000.00%
Free Cash Flow to Firm to Interest Expense
0.00 590.20 -161.99 0.00 -119.22 0.00 -67.20 0.00 -24.50 -8.55
Operating Cash Flow to Interest Expense
0.00 -70.00 -98.00 0.00 -63.00 0.00 -2.00 0.00 26.00 -50.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 -70.00 -101.00 0.00 -73.00 0.00 -6.00 0.00 25.00 -50.50
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.39 0.08 0.09 0.09 0.09 0.10 0.19 0.21 0.22 0.23
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
13.80 3.34 3.38 3.09 2.86 2.72 5.39 5.26 5.37 5.27
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-493 -481 -444 -444 -430 -404 -388 -374 -479 -459
Invested Capital Turnover
-1.25 -0.70 -0.24 -0.25 -0.26 -0.26 -0.57 -0.60 -0.58 -0.60
Increase / (Decrease) in Invested Capital
-292 -642 102 80 63 77 56 70 -49 -55
Enterprise Value (EV)
696 359 288 475 387 564 318 376 354 419
Market Capitalization
1,888 1,497 1,332 1,485 1,337 1,430 1,413 1,385 1,398 1,363
Book Value per Share
$9.68 $9.07 $8.22 $7.74 $6.98 $6.17 $8.20 $6.98 $6.18 $5.30
Tangible Book Value per Share
$9.68 $9.07 $8.22 $7.74 $6.98 $6.17 $8.20 $6.98 $6.18 $5.30
Total Capital
699 657 600 566 520 462 707 635 612 533
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 47 48
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 47 48
Net Debt
-1,192 -1,138 -1,044 -1,010 -950 -866 -1,095 -1,009 -1,044 -944
Capital Expenditures (CapEx)
2.00 0.00 3.00 5.00 10 6.00 4.00 0.00 1.00 1.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-125 -135 -118 -124 -117 -112 -135 -146 -177 -188
Debt-free Net Working Capital (DFNWC)
924 874 836 806 682 647 860 823 912 790
Net Working Capital (NWC)
924 874 836 806 682 647 860 823 912 790
Net Nonoperating Expense (NNE)
16 15 20 17 15 17 -7.20 19 19 22
Net Nonoperating Obligations (NNO)
-1,192 -1,138 -1,044 -1,010 -950 -866 -1,095 -1,009 -1,044 -944
Total Depreciation and Amortization (D&A)
2.00 -1.00 -2.00 -2.00 2.00 -9.00 -3.00 -5.00 -4.00 -3.00
Debt-free, Cash-free Net Working Capital to Revenue
-28.86% -120.54% -99.16% -102.48% -97.50% -95.73% -56.96% -59.11% -67.30% -72.87%
Debt-free Net Working Capital to Revenue
213.57% 780.36% 702.52% 666.12% 568.33% 552.99% 362.87% 333.20% 346.77% 306.20%
Net Working Capital to Revenue
213.57% 780.36% 702.52% 666.12% 568.33% 552.99% 362.87% 333.20% 346.77% 306.20%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 ($1.08) ($0.05) ($1.02) ($1.00) ($1.07)
Adjusted Weighted Average Basic Shares Outstanding
72.24M 72M 73M 73.20M 74.60M 74M 86.20M 91.10M 91.40M 90.10M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 ($1.08) ($0.05) ($1.02) ($1.00) ($1.07)
Adjusted Weighted Average Diluted Shares Outstanding
72.24M 72M 73M 73.20M 74.60M 74M 86.20M 91.10M 91.40M 90.10M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
72.41M 73.01M 73.11M 74.50M 74.86M 90.86M 90.95M 91.43M 91.51M 105.84M
Normalized Net Operating Profit after Tax (NOPAT)
-49 -52 -60 -58 -56 -64 2.80 -74 -74 -72
Normalized NOPAT Margin
-148.48% -152.35% -240.80% -200.34% -175.00% -205.48% 1.93% -190.26% -153.13% -277.31%
Pre Tax Income Margin
-196.97% -197.06% -312.00% -255.17% -215.63% -258.06% -2.76% -238.46% -191.67% -357.69%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 -66.00 -77.00 0.00 -68.00 0.00 -3.00 0.00 -91.00 -51.50
NOPAT to Interest Expense
0.00 -51.80 -60.20 0.00 -56.00 0.00 -11.20 0.00 -73.50 -36.05
EBIT Less CapEx to Interest Expense
0.00 -66.00 -80.00 0.00 -78.00 0.00 -7.00 0.00 -92.00 -52.00
NOPAT Less CapEx to Interest Expense
0.00 -51.80 -63.20 0.00 -66.00 0.00 -15.20 0.00 -74.50 -36.55
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Arcus Biosciences' Financials

When does Arcus Biosciences's fiscal year end?

According to the most recent income statement we have on file, Arcus Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Arcus Biosciences' net income changed over the last 8 years?

Arcus Biosciences' net income appears to be on an upward trend, with a most recent value of -$283 million in 2024, rising from -$17.97 million in 2016. The previous period was -$307 million in 2023.

What is Arcus Biosciences's operating income?
Arcus Biosciences's total operating income in 2024 was -$330 million, based on the following breakdown:
  • Total Gross Profit: $258 million
  • Total Operating Expenses: $588 million
How has Arcus Biosciences revenue changed over the last 8 years?

Over the last 8 years, Arcus Biosciences' total revenue changed from $0.00 in 2016 to $258 million in 2024, a change of 25,800,000,000.0%.

How much debt does Arcus Biosciences have?

Arcus Biosciences' total liabilities were at $665 million at the end of 2024, a 5.1% increase from 2023, and a 1,716.0% increase since 2017.

How much cash does Arcus Biosciences have?

In the past 7 years, Arcus Biosciences' cash and equivalents has ranged from $57.94 million in 2019 to $206 million in 2022, and is currently $150 million as of their latest financial filing in 2024.

How has Arcus Biosciences' book value per share changed over the last 8 years?

Over the last 8 years, Arcus Biosciences' book value per share changed from 0.00 in 2016 to 5.30 in 2024, a change of 530.0%.



This page (NYSE:RCUS) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners